Abstract | OBJECTIVE: METHODS: RESULTS: Of 396 patients who received erenumab, 38% (n = 149) met inclusion criteria. After 3 months, 51% (n = 76) and 20% (n = 30) patients achieved ≥ 50% and ≥ 75% reduction in monthly headache days, respectively. Monthly pain medications intake decreased from 46.1 ± 35.3 to 16.8 ± 13.9 (p < 0.001), while monthly headache days decreased from 25.4 ± 5.4 to 14.1 ± 8.6 (p < 0.001). Increasing efficacy of erenumab over the study period was observed. Allodynia was a negative predictive factor of erenumab response (odds ratio = 0.47; p = 0.03). Clinical conversion to episodic migraine with no medication overuse was observed in 64% (n = 96) patients. No serious adverse events were observed. CONCLUSIONS:
|
Authors | Umberto Pensato, Carlo Baraldi, Valentina Favoni, Maria Michela Cainazzo, Paola Torelli, Pietro Querzani, Alessia Pascazio, Davide Mascarella, Eleonora Matteo, Simone Quintana, Gian Maria Asioli, Pietro Cortelli, Giulia Pierangeli, Simona Guerzoni, Sabina Cevoli |
Journal | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
(Neurol Sci)
Vol. 43
Issue 2
Pg. 1273-1280
(Feb 2022)
ISSN: 1590-3478 [Electronic] Italy |
PMID | 34224026
(Publication Type: Journal Article)
|
Copyright | © 2021. Fondazione Società Italiana di Neurologia. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Calcitonin Gene-Related Peptide Receptor Antagonists
- erenumab
|
Topics |
- Antibodies, Monoclonal, Humanized
- Calcitonin Gene-Related Peptide Receptor Antagonists
- Headache
- Headache Disorders, Secondary
(drug therapy)
- Humans
- Migraine Disorders
(drug therapy)
- Prospective Studies
|